Deenova Continues to Set Records in Its Market Growth in France, With 4 New Contracts Awarded by Leading French Hospitals
26.7.2022 07:00:00 EEST | Business Wire | Press release
Boosting its unstoppable rise in the French market, Deenova announces four new contract awards, for its pioneering and unrivaled D3 series. Three AIDE Pick and two AIDE Cut robots, Deenova’s D3 latest innovative solutions, has been awarded by the Center Hospitalier in Bagnères de Bigorre by winning the competitive UniHA tender. Simultaneously Deenova reports new RESAH contracts for its long established and market leading ACCED robot at University Hospital of Saint-Ètienne and at Center Hospitalier intercommunal de Poissy - Saint-Germain-en-Laye. Finally, Center Hospitalier de Tourcoing, existing Deenova Acced and ASTUS customer, confirms its trust in Deenova D3 solutions with 20 additional ASTUS secured cabinets, through the UniHA tendering.
Loïc Bessin, Managing Director of Deenova France, stated: " With these new contracts, we are now exceeding the bar of 100 Hospital Pharmacy automation solutions in France spread over more than 40 healthcare institutions, which makes Deenova by far the number 1 company in France, with our solutions referenced both at UniHA and RESAH.”
Christophe Jaffuel, Chief Commercial Officer of Deenova, added: "Those recent tender awards are extremely significant for us, not only they confirm our dominant market share in France, with a third year of very strong consecutive growth, but also the early acceptance of our recently launched modular AIDE product line, as well as the solidity of our partnerships with RESAH and UniHA. A positive trend, that we expect to continue in future.”
The Center Hospitalier of Bagnères de Bigorre is a HAS certified facility in the Pyrenees area, offering different services such as functional rehabilitation, general medicine, geriatric SSR, LTC, radiology and therapeutic education, as well as a nursing home.
The University Hospital of Saint-Ètienne is located in the heart of the Auvergne-Rhône-Alpes region. Its activities are organized around 16 poles and 68 services, with 1920 beds distributed over the 3 main sites. The 8,350 professionals care annually for over 170,000 patients in hospitalization and sessions and more than 500,000 in consultations.
The Center hospitalier intercommunal de Poissy - Saint-Germain-en-Laye is a member of the Groupement hospitalier de territoire des Yvelines Nord and is a public institution of reference in care, teaching, and research. It has specialized activity poles with quality of care and safety certified by HAS.
Centre Hospitalier de Tourcoing is a regional hospital with 780 beds, located in the northeast of the The European Metropolis of Lille and a group member of the GHT Lille Métropole Flandre Intérieure. It serves an area of 230 municipalities, with a population of 1.5 million inhabitants, and more than 2000 professionals working together to provide patient care.
Since 2004, Deenova is the undisputed leading supplier of mechatronics solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry.
Deenova’s unique, patented and fully integrated solutions ease the healthcare providers’ growing pressures to improve patient safety, reduce therapy errors, minimize waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Please visit www.deenova.com for additional information on its market leading solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005393/en/
Contact information
Contacts at Deenova:
Loïc Bessin, Christophe Jaffuel, Martina Buccianti
m.buccianti@deenova.com, +39 0523 785311
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
Andersen Global Adds Depth to Tax and Global Mobility Capabilities in Germany30.6.2026 16:30:00 EEST | Press release
Andersen Global strengthens its presence through a Collaboration Agreement with Lohr and Company (L+C), a senior-led tax advisory platform, providing practical, responsive solutions in tax compliance, cross-border tax, global mobility, and transfer pricing. Headquartered in Germany with a presence in Austria, L+C advises large multinationals and family-owned companies, family offices, foundations, and high-net-worth individuals. The firm, founded in 2001, specializes in areas such as global mobility, M&A, international tax law, country-by-country reporting, and transfer pricing, including Pillar 2 reporting. Additionally, L+C supports clients with trusts and foundations, tax compliance, payroll and financial accounting, and private financial advisory services. “Collaborating with Andersen Global represents an important step in expanding our international capabilities and strengthening the value we provide to clients navigating increasingly complex cross-border matters,” said Jörg-Andre
90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 16:00:00 EEST | Press release
As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations address this challenge, Lenovo is expanding its global Security Services portfolio with a revamped cyber resiliency framework and end-to-end security offerings designed to provide a single point of accountability, help organizations reduce security complexity, cut system downtime by up to 50%, and lower
SC Therapeutics Initiates REACH2 Trial for Refractory Chronic Cough30.6.2026 16:00:00 EEST | Press release
SC Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that deactivate mechano-sensitive ion channels (MSCs) to treat respiratory and cardiovascular disease, today reports initiation of the REACH2 trial. The study will evaluate the Company's lead product candidate in patients with refractory chronic cough (RCC) – a debilitating condition for which no disease-modifying treatment options currently exist. The trial will be run in three major cough centers across the UK. A Novel, Disease-Modifying Mechanism of Action SC0032, SC Therapeutics' most advanced product candidate, is a proprietary therapeutic aerosol composed entirely of ions endogenous to human airways. Unlike current symptomatic investigational drugs – including P2X3 receptor antagonists and neurokinin-1 (NK1) receptor antagonists that seek to dampen neural hypersensitivity through receptor blockade – SC0032’s approach directly addresses the upstream inflammatory drivers of chronic cough. By acting to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom